Cardiff Oncology to Participate in Three Upcoming Investor Conferences 

Rhea-AI Summary

Cardiff Oncology (Nasdaq: CRDF) announced that management will participate in three investor conferences in March 2026: TD Cowen on 03/04/26, Barclays on 03/10/26 and Leerink Partners on 03/11/26. Interested parties can view live webcasts and replays via the company’s Events page.

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences in March 2026.  

TD Cowen 46th Annual Health Care Conference
Date: 03/04/26

Barclays 28th Annual Global Healthcare Conference
Date: 03/10/26

Leerink Partners Global Healthcare Conference 2026
Date: 03/11/26

Interested parties can register for and access the live webcast for the conferences by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation. 

About Cardiff Oncology, Inc.  
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (“mCRC”), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

For more information, please visit https://www.cardiffoncology.com.

Investor Contact: 
Candice Masse 
Astr Partners 
candice.masse@astrpartners.com   

Media Contact:  
Amy Bonanno  
Lyra Strategic Advisory  
abonanno@lyraadvisory.com 

FAQ

When will Cardiff Oncology (CRDF) present at the TD Cowen 46th Annual Health Care Conference?

Cardiff Oncology will present on March 4, 2026. According to the company, investors can register for a live webcast and access a replay after the presentation via the Events section of the company website.

How can investors watch Cardiff Oncology (CRDF) at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026?

Investors can watch a live webcast of the Barclays presentation on March 10, 2026. According to the company, registration and the replay are available through the Events page on the Cardiff Oncology website.

Is there a replay available for Cardiff Oncology’s (CRDF) Leerink Partners Global Healthcare Conference presentation on March 11, 2026?

Yes, a replay will be available after the presentation concludes. According to the company, the live webcast and subsequent replay can be accessed by registering through the Events section on the company website.

What topics will Cardiff Oncology (CRDF) management likely cover in the March 2026 investor conferences?

Management will discuss company strategy and clinical-stage PLK1 inhibition programs. According to the company, presentations typically cover program updates and investor Q&A relevant to Cardiff Oncology’s oncology pipeline.

Where can I register to attend Cardiff Oncology (CRDF) conference webcasts in March 2026?

Register via the Cardiff Oncology website Events section to access live webcasts and replays. According to the company, the Events page lists registration links and post-event replay availability for each conference.